溶瘤病毒
病毒
鼻咽癌
更昔洛韦
爱泼斯坦-巴尔病毒
溶解循环
病毒学
免疫学
细胞溶解
单纯疱疹病毒
联合疗法
癌症研究
免疫系统
细胞毒性
生物
医学
放射治疗
人巨细胞病毒
内科学
体外
生物化学
作者
Maarten A. Wildeman,Zlata Novalić,Sandra A.W.M. Verkuijlen,Hedy Juwana,Alwin D. R. Huitema,I. Bing Tan,Jaap M. Middeldorp,Jan Paul de Boer,Astrid E. Greijer
标识
DOI:10.1158/1078-0432.ccr-12-0574
摘要
Abstract Purpose: Nasopharyngeal carcinoma (NPC) is causally linked to Epstein–Barr virus (EBV) infection. Because all tumor cells carry EBV, the virus itself is a potential target for therapy. In these tumor cells, EBV hides in a latent state and expresses only a few non-immunogenic proteins for EBV maintenance and contributes to tumor growth. We developed a cytolytic virus activation (CLVA) therapy for NPC treatment, reactivating latent EBV, triggering immune recognition, and inducing susceptibility to antiviral therapy. Experimental Design: CLVA therapy combines gemcitabine (GCb) and valproic acid (VPA) for virus activation and tumor clearance with (val)ganciclovir (GCV) as the antiviral drug to block virus replication and kill proliferating virus-infected cells. CLVA treatment was optimized and validated in NPC cell lines and subsequently tested in 3 Dutch patients with NPC that was refractory to conventional treatment. Results: In NPC cell lines, both GCb and VPA can induce the lytic cycle of EBV. Their combination resulted in a strong synergistic effect. The addition of GCV resulted in higher cytotoxicity compared with chemotherapy alone, which was not observed in EBV-negative cells. CLVA therapy was analyzed in 3 patients with end-stage NPC. Patients developed increased levels of viral DNA in the circulation originating from apoptotic tumor cells, had disease stabilization, and experienced improved quality of life. Conclusions: Our results in the initial CLVA-treated patients indicate that the therapy had a biological effect and was well tolerated with only moderate transient toxicity. This new virus-specific therapy could open a generic approach for treatment of multiple EBV-associated malignancies. Clin Cancer Res; 18(18); 5061–70. ©2012 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI